Unlocking the
power of
neuroplastogens.
Scientific Approach
We pioneer & engineer novel therapies through next-generation precision neuroscience.
Psilera was created by chemists who chose to champion psychedelics & neuroplastogens because of their untapped potential.
Neuroplastogens & next-generation psychedelics have the ability to improve the quality of life of patients suffering from a wide range of conditions.
Lead Clinical Therapy:
PSIL-006
Different By Design:
PSIL-006 is a next-generation, psilocybin derivative with broad applicability and a patient-friendly profile.
Because of its non-hallucinogenic profile, PSIL-006 is designed to be a good candidate for take-home use and insurability.
Preclinical Data Shows:
- PSIL-006 demonstrates no treatment-limiting side effects, such as hallucinations.
- Animal model testing demonstrated efficacy with a single dose.
- PSIL-006 demonstrates a positive effect on serotonin receptor 2A (5-HT2A) which is commonly targeted in the brain for the rapid treatment of psychiatric conditions.
In-House Research Pipeline
Collaborated Programs
Collaborated with AtaiBeckley on programs covering all granted and pending patents related to DMT and other related psychedelics from the DMT (N,N-dimethyltryptamine) Patent Estate licensing agreement.
Psilera is eligible for payments related to certain future development milestones, as well as certain royalties on commercial product sales.
Publications
2026
2025
2024
